Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg od and 150 mg od) Given During 12 Weeks in Lamellar Ichthyosis

NCT00282724 is registered in ClinicalTrials.gov with Stiefel, a GSK Company as lead sponsor.

NCT NCT00282724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00282724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg od and 150 mg od) Given During 12 Weeks in Lamellar Ichthyosis
Lead sponsor
Stiefel, a GSK Company
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2006
Completion date
April 30, 2007
Enrollment
98 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ichthyosis, lamellar